June 22, 2022
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
June 7, 2022
Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research
May 19, 2022
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
May 16, 2022
Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest
May 16, 2022
Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
May 12, 2022
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates
May 11, 2022
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
May 9, 2022
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
May 5, 2022
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director Nominees
May 5, 2022
Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter
Displaying 41 - 50 of 116